Markets

ResMed Balances Weak Q3 with Favorable Fundamentals - Analyst Blog

On June 11, 2014, we issued an updated research report on ResMed, Inc. ( RMD ). ResMed delivered a weak third-quarter fiscal 2014 with in-line earnings and revenues that lagged the Zacks Consensus Estimate. However, the still-untapped obstructive sleep apnea (OSA) market should catalyze growth in the near term.

In the quarter under review, ResMed reported adjusted earnings of 63 cents per share, which although up 8.6% year over year, were merely in line with the Zacks Consensus Estimate. Revenues of $397.8 million increased 3.7% but fell below the Zacks Consensus Estimate of $399 million.

Given the difficult year-over-year comparable and challenging market conditions in the U.S., revenues in the Americas grossed $216.1 million, flat with the year-ago quarter number. Moreover, the ongoing headwind related to reimbursement issues across the world along with the recent healthcare reform in the U.S. continues to take a toll on the company's business.

Nevertheless, ResMed continues to gain from a solid foothold in the huge sleep-disordered breathing (SDB) market. According to the company, several initiatives are now being taken to increase awareness regarding OSA. This has led to improved understanding of the role of SDB treatment in the management of cardiac, neurologic, metabolic and related disorders, and has driven an increase in home-based diagnosis. This, in turn, promises a growing SDB market for the company in the near future.

Continuous solid overseas growth amid several macroeconomic uncertainties is also encouraging. Robust pipeline development also bolsters confidence. Meanwhile, ResMed has been rewarding its shareholders with attractive share repurchases and dividends thus upholding investor faith.

The stock currently carries a Zacks Rank #3 (Hold).

Key Picks from the Sector

Better-ranked stocks that warrant a look in the broader medical sector include Amedisys Inc. ( AMED ), RadNet, Inc. ( RDNT ) and HEALTHSOUTH Corp. ( HLS ). All these stocks carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

RESMED INC (RMD): Free Stock Analysis Report

AMEDISYS INC (AMED): Free Stock Analysis Report

HEALTHSOUTH CP (HLS): Free Stock Analysis Report

RADNET INC (RDNT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

RDNT AMED RMD

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More